GLP-1 Receptor Agonists

Renal

Records checked

Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk

Qualified clinical review None on record

Withheld from the index. This page sets out the indexed clinical-record picture for all 17 compounds in scope, at one endpoint.

Every compound in scope is marked high impact and none has a qualified clinical reviewer recorded, so this page is built, checked and served with a noindex directive and left out of the sitemap. Nothing on it has been removed or softened. Recording a named reviewer publishes it unchanged on the next build. How the gate works.

Records whose assigned subject headings cover kidney function, filtration rate, albuminuria or renal disease states. 10 of the 186 records indexed across this publication's scope carry at least one of them, covering 7 of the 17 compounds.

Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.

Record coverage by compound and record class

Indexed records carrying a renal subject heading, by compound and by the record class assigned to each record. Bracketed numbers are the records themselves, listed below.
CompoundPh 3Ph 2Ph 1Trial, no phaseReviewOtherAll
Amylin0000000
Cagrilintide000001 [2]1
Dulaglutide0001 [6]001
Eloralintide0000000
Exenatide0000000
GLP-100001 [7]01
Liraglutide0001 [10]001
Lixisenatide000002 [8, 9]2
Maridebart cafraglutide0000000
Mazdutide0000000
Orforglipron0000000
Petrelintide0000000
Pramlintide0000000
Retatrutide0001 [1]01 [3]2
Semaglutide0002 [4, 5]002
Survodutide0000000
Tirzepatide0000000

Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.

A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.

Subject headings that place a record here

The full set is fixed and printed here so the assignment can be checked by hand against the method. 10 of the 10 headings in the set occur on at least one record in scope.

Subject headingRecords
Diabetic Nephropathies6
Glomerular Filtration Rate6
Albuminuria3
Creatinine2
Kidney2
Kidney Diseases1
Kidney Failure, Chronic1
Kidney Function Tests1
Renal Insufficiency1
Renal Insufficiency, Chronic1

The records

10 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.

Trial, no phase assigned — 5 records

No.IdentifierYearRecordModelIndexed underSubject headings
1pmid:411604222026Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · Clinical Trial Protocol, research-article
otherRetatrutideHumans; Diabetes Mellitus, Type 2; Obesity; Fatty Acids; Peptides; Hypoglycemic Agents; Kidney Function Tests; Glomerular Filtration Rate
4pmid:401626422025Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
The New England journal of medicine · Equivalence Trial, Multicenter Study
human trialSemaglutideHumans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Double-Blind Method; Aged; Middle Aged
5pmid:387852092024Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
The New England journal of medicine · Multicenter Study, Randomized Controlled Trial
human trialSemaglutideHumans; Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate; Injections, Subcutaneous; Double-Blind Method
6pmid:311895092019Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Lancet (London, England) · Multicenter Study, Randomized Controlled Trial
human trialDulaglutideHumans; Diabetic Nephropathies; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Recombinant Fusion Proteins; Hypoglycemic Agents; Glomerular Filtration Rate
10pmid:288540852017Liraglutide and Renal Outcomes in Type 2 Diabetes
The New England journal of medicine · Comparative Study, Randomized Controlled Trial
human trialLiraglutideHumans; Diabetic Nephropathies; Kidney Failure, Chronic; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Hypoglycemic Agents; Glomerular Filtration Rate

Review or synthesis — 1 record

No.IdentifierYearRecordModelIndexed underSubject headings
7pmid:314220622019Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
The lancet. Diabetes & endocrinology · Meta-Analysis, Research Support, Non-U.S. Gov't
otherGLP-1Humans; Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Treatment Outcome; Randomized Controlled Trials as Topic; Glucagon-Like Peptide-1 Receptor Agonists

Not a registered trial record — 4 records

No.IdentifierYearRecordModelIndexed underSubject headings
2pmid:422283342026Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Clinical pharmacokinetics · research-article, Multicenter Study
human trialCagrilintideHumans; Liver Diseases; Hypoglycemic Agents; Injections, Subcutaneous; Area Under Curve; Adult; Aged; Middle Aged
3pmid:392129002025Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice
Endocrine · Comparative Study
rodentRetatrutideKidney; Animals; Mice, Inbred C57BL; Mice; Diabetic Nephropathies; Diabetes Mellitus, Experimental; Blood Glucose; Fatty Acids
8pmid:302925892018Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
The lancet. Diabetes & endocrinology · Research Support, Non-U.S. Gov't
otherLixisenatideHumans; Kidney Diseases; Albuminuria; Diabetes Mellitus, Type 2; Peptides; Glomerular Filtration Rate; Treatment Outcome; Middle Aged
9pmid:284494022017Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial
Diabetes, obesity & metabolism · Comparative Study, Research Support, Non-U.S. Gov't
human trialLixisenatideKidney; Humans; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Insulin; Peptides; Hypoglycemic Agents; Glomerular Filtration Rate

What this page does not say

  • It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
  • It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
  • It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
  • It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.